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objective. To determine whether probiotic prophylaxes reduce the odds of Clostridium difﬁcile infection (CDI) in adults and children.
design. Individual participant data (IPD) meta-analysis of randomized controlled trials (RCTs), adjusting for risk factors.
methods. We searched 6 databases and 11 grey literature sources from inception to April 2016. We identiﬁed 32 RCTs (n= 8,713); among
them, 18 RCTs provided IPD (n= 6,851 participants) comparing probiotic prophylaxis to placebo or no treatment (standard care). One
reviewer prepared the IPD, and 2 reviewers extracted data, rated study quality, and graded evidence quality.
results. Probiotics reduced CDI odds in the unadjusted model (n= 6,645; odds ratio [OR] 0.37; 95% conﬁdence interval [CI], 0.25–0.55)
and the adjusted model (n= 5,074; OR, 0.35; 95% CI, 0.23–0.55). Using 2 or more antibiotics increased the odds of CDI (OR, 2.20; 95% CI,
1.11–4.37), whereas age, sex, hospitalization status, and high-risk antibiotic exposure did not. Adjusted subgroup analyses suggested that,
compared to no probiotics, multispecies probiotics were more beneﬁcial than single-species probiotics, as was using probiotics in clinical
settings where the CDI risk is ≥5%. Of 18 studies, 14 reported adverse events. In 11 of these 14 studies, the adverse events were retained in
the adjusted model. Odds for serious adverse events were similar for both groups in the unadjusted analyses (n= 4,990; OR, 1.06; 95% CI,
0.89–1.26) and adjusted analyses (n= 4,718; OR, 1.06; 95% CI, 0.89–1.28). Missing outcome data for CDI ranged from 0% to 25.8%.
Our analyses were robust to a sensitivity analysis for missingness.
conclusions. Moderate quality (ie, certainty) evidence suggests that probiotic prophylaxis may be a useful and safe CDI prevention
strategy, particularly among participants taking 2 or more antibiotics and in hospital settings where the risk of CDI is ≥5%.
trial registration. PROSPERO 2015 identiﬁer: CRD42015015701
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Clostridium difﬁcile infection (CDI) is the leading cause of
hospital-associated infectious diarrhea.1 Diarrhea is the most
common presentation; however, CDI may result in more
serious sequelae including pseudomembranous colitis, toxic
megacolon, and death,2,3 and mortality ranges from 5% to
10%.3 Frequent recurrence, affecting ~20% of treated
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participants, is particularly challenging for CDI management.4
Most CDI cases occur in higher-income countries,5 but data
from middle- and low-income countries are lacking. Surveil-
lance data suggest that the incidence density ranges between
2.45 and 7.5 per 10,000 patient days or between 9 and 80 per
10,000 patient admissions.2,6–8 An individual patient’s risk of
developing CDI differs based on numerous host and envir-
onmental factors,2,6,9,10 most importantly antibiotic exposure,
which is thought to disrupt the intestinal microbiota, allowing
C. difﬁcile to proliferate.6
Probiotics, deﬁned as live microorganisms that, when admi-
nistered in adequate amounts, may confer a health beneﬁt on
the host, are a potential CDI prevention strategy.11 A 2013
Cochrane meta-analysis of 23 randomized controlled trials
(RCTs) demonstrated a 64% decrease (95% conﬁdence interval
[CI], 49%–73%) in CDI incidence with probiotic prophylaxis.12
The results of a subsequent large RCT (n= 2,941) were
indeterminate; however, CDI events were less frequent than
anticipated. An updated aggregate data meta-analysis
incorporating the study showed that the beneﬁcial effect of the
probiotic remained.13 A recent review of clinical practice
guidelines on CDI prevention14 found that recommendations
mainly revolved around core strategies (eg, education of
healthcare staff on CDI, patient isolation, antimicrobial
stewardship, and utilization of disinfectants), but none recom-
mend probiotics for prophylaxis.15–19 Guidelines cited concerns
regarding insufﬁcient evidence,17,20 too much weight given to
studies with high baseline CDI risk,16 and safety concerns.16,20
To address some of these concerns and to further investigate
the effectiveness and safety of probiotics on populations and
interventions with varying characteristics, we conducted an
individual participant data (IPD) meta-analysis. Our objective
was to determine whether adding probiotics to an antibiotic
regimen reduces the incidence of CDI among children and
adults, when adjusting for age, sex, hospitalization status, the
number of antibiotics taken, and the administration of high-risk
antibiotics.
methods
We registered the protocol for this IPD meta-analysis in the
PROSPERO registry in January 2015.21
Searches
We considered all studies deemed eligible in a previous com-
prehensive systematic review on probiotics for the prevention
of CDI (Appendix Methods 1),12 and we updated the search on
April 11, 2016 (Appendix Tables 1 and 2).
Study Selection
Two reviewers independently screened titles, abstracts, and
full-text articles for eligibility and resolved differences through
consensus. We included RCTs with children (0 to <18 years)
or adults administered antibiotics (ie, any reason or duration)
with concomitant probiotics (ie, any dose, species, strain, or
duration), compared to placebo, alternative prophylaxis, or no
treatment (standard care), and that reported CDI as an out-
come. The latter was our primary outcome, deﬁned as either
diarrhea with laboratory conﬁrmation of C. difﬁcile, presence
of pseudomembranes on sigmoidoscopy or colonoscopy,
histological diagnosis of C. difﬁcile, or diagnosis of toxic
megacolon.22 Our secondary outcome was the incidence of
serious adverse events (SAEs).
Data Extraction and Quality Assessment
We contacted the authors of all eligible studies and requested
ethics-approved, deidentiﬁed data including participants’
allocated treatment, age, length of hospital stay, CDI history,
antibiotics given, probiotics given, presence of diarrhea, CDI
diagnosis, and SAEs. We also requested any information on
missing outcome data, such as participants lost to follow up
and participants who had diarrhea but no C. difﬁcile test.
Reviewer pairs (B.C.J., J.G., L.L.) independently assessed risk
of bias based on the Cochrane Handbook for Systematic Reviews
of Interventions.23 For studies from the previous review, we used
the previous assessment,12 with 6 modiﬁcations (Appendix
Methods 2). For the overall certainty in estimates for each
outcome, we used Grading of Recommendations, Assessment,
Development and Evaluation (GRADE), independently and in
duplicate.24 Publication bias was evaluated with a funnel plot.25
Data Synthesis and Analysis
We pooled IPD across trials and analyzed it using a generalized
linear mixed model using the SAS GLIMMIX procedure using
SAS/STAT version 9.4 software (SAS Institute, Cary, NC) and
calculated the odds ratio (OR) and 95% CIs. We considered
the study level as a random effect and the participant variables
as ﬁxed. For our adjusted analysis, based on known CDI risk
factors, variables available across datasets, and data provided
by authors, we developed a model adjusting for 5 variables: age
(years),10 sex, hospitalization status, use of multiple anti-
biotics, and exposure to high-risk antibiotics (third- and
fourth-generation cephalosporins, lincosamides, and ﬂuor-
oquinolones).6 Only hospitalized participants had SAEs; thus,
we did not adjust for this variable.
Statistical heterogeneity was evaluated using the I2 value,
where an I2 value of 0 to 40% represented low heterogeneity and
an I2 value of 30%–60% represented moderate heterogeneity.26
We used Review Manager version 5.3 software (Copenhagen,
Denmark) for aggregate data meta-analyses and funnel plots.
We used SPSS version 20 software (IBMArmonk, NY) and SAS/
STAT version 9.4 software for data cleaning and analysis,
respectively. We used Stata version 13 software (StataCorp,
College Station, TX) to graph the IPDmeta-analysis forest plots.
Given the low event rate for CDI and SAEs (<10%), the OR
approximates the relative risk (RR). Thus, we reported relative
risk reduction (RRR) for ease of interpretation.
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Subgroup Analyses
We conducted 4 a priori subgroup analyses. First, as an
approximation of baseline CDI incidence, we examined
studies with low (<5%) control-group event rates versus those
with rates ≥5%.16 Second, we compared no probiotics (ie,
control group) to single-species probiotics. Third, we com-
pared no probiotics to multispecies or multistrain probiotics.13
Fourth, we looked at probiotic dose, where participants in the
control group had zero colony-forming units (CFU) per day
(ie, control group), and we examined the effect of increasing
the dose by 1 billion CFU per day in the intervention group.27
Sensitivity Analyses
We conducted 4 a priori sensitivity analyses on our primary
outcome. First, we compared the unadjusted analysis (18 stu-
dies, n= 6,645) with the pooled estimate of effect based on
aggregate data (18 studies, n= 6,447). Second, we compared
the adjusted analysis (13 studies; n= 5,074) with the pooled
estimate of effect based on aggregate data (13 studies;
n= 5,341). Third, for the adjusted analysis of CDI, we
categorized age (infants 0 to <1 year, children 1 to <18 years,
adults 18 to <65 years, older adults 65 + years) to determine
whether age groups are more predictive of CDI than
continuous linear age. We discerned infants from children
because before 1 year of age, C. difﬁcile colonization is
common and does not reﬂect CDI.28 Fourth, for the adjusted
analysis, we accounted for clustering using generalized
estimation equations (GEE) using the SAS GENMODprocedure.
Handling Missing Participant Data
Participants with no reported outcome for CDI were con-
sidered as having missing outcome data. If participants with
missing CDI outcome data had reported no diarrhea, we
assumed they did not have CDI. If participants had reported
diarrhea but no CDI test result, we considered this missing
outcome data. We conducted a sensitivity analysis using the
PROCMI procedure in SAS to impute missing data to create 5
imputed data sets. We examined the effect of multiple impu-
tation on regression estimates using PROC MIANALYZE.
results
Data Selection and Data Obtained
Of 2,021 articles, we obtained IPD from 18 of 32 conﬁrmed
eligible trials29–46 with IPD for 6,851 of 8,713 participants
(78.6% of all available data). Among our sample of 6,851,
participants had 120 CDI events and 613 SAEs (Table 1). There
were 11 formulations of probiotics given, with doses ranging
from 0.1 to 900 billion CFUs per day. Most studies (88.9%)
used placebo as a control and were conducted in adult hospi-
talized participants (72.2%) (Table 1). The proportion of par-
ticipants on high risk antibiotics at any given time ranged from
0%30,31 to 85.4%44 (Table 2). For the outcome CDI, 2 studies
(11.1%) did not report participant level data on antibiotics
taken,38,39 and 3 studies (16.7%) did not report age.36,37,43
Thus, 1,777 of 6,851 participants (26%) were excluded from
the adjusted CDI model (n= 5,074). The length of hospital stay
and CDI history were not available for most datasets and were
not included in the model. In terms of missing outcome data
for CDI, study results ranged from zero29,32,35,38,40,41,44–46 to
25.8%.33 For our secondary outcome, 14 of 18 studies provided
IPD for SAEs.29–33,35–38,40,41,44–46 Our adjusted model was
based on 11 of these 14 studies because 3 studies did not report
age (16.7%).36,37,43 Thus, 272 of 4,990 participants (5.5%) were
excluded from this model (n= 4,718).
Risk of Bias Assessment
For the primary outcome CDI, 4 studies were at high risk of
bias for incomplete outcome data because >10% of partici-
pants either had no data provided or had diarrhea but no CDI
test30,31,33,39 (Appendix Figure 1). Another study was at high
risk of bias for blinding of participants and personnel along
with blinding for outcome assessment.42 For SAEs, 1 study was
at high risk of bias for incomplete outcome data because
authors reported SAEs but did not provide the data.34 We
identiﬁed 2 studies that were at high risk of bias for blinding
both of participants and personnel and of outcome data.30,42
Overall, for both CDI and SAEs, 2 studies were at high risk for
selective reporting30,34 and 5 studies were at high risk of other
bias for potential conﬂict of interest due to industry
funding.35–38,45
There was no suspected publication bias for CDI among the
included studies, which was similar for all eligible studies and
studies with data available (Appendix Figure 2). (Figure 1)
Primary Outcome: Clostridium difﬁcile Infection
Of the 18 studies reporting on CDI outcomes, 38 of 3,384 of cases
(1.1%) were in the intervention group, and 82 of 3,262 (2.5%)
were in the control group (Table 2). Probiotic prophylaxis
reduced the unadjusted odds of CDI (OR, 0.37; 95% CI,
0.25–0.55; P< .0001; n=6,645; Figure 2), similar to the pooled
estimate for the 14 studies for which IPD was not obtained (OR,
0.30; 95%CI, 0.19–0.47; P< .0001; n=2,266; Appendix Figure 3).
Of the 13 studies included in the adjusted model, probiotics sig-
niﬁcantly reduced the CDI (OR, 0.35; 95% CI, 0.23–0.55;
P< .0001; n=5,074; Figure 2). The use of 2 or more antibiotics
signiﬁcantly increased the risk of CDI (OR, 2.20; 95% CI,
1.11–4.37; P= .0243), whereas age, sex, hospitalization status, and
high-risk antibiotic exposure did not.
Multiple imputation sensitivity analysis provided similar
regression estimates to the adjusted analysis (OR, 0.37; 95%
CI, 0.25–0.56; P< .001).
Subgroup Analyses
A control group event rate of ≥5% was signiﬁcantly associated
with CDI in the adjusted model (OR, 16.33; 95% CI, 7.79–
34.26; P< .0001; n= 5074) (Figure 2) and had signiﬁcant
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table 1. Characteristics of Included Studies
Probiotics Group
(N= 3,482)a
Control Group
(N= 3,369)
Study Probiotic Group
Dose,
Billion
CFU/d
Control
Group n CDI SAE n CDI SAE
Inpatient,
%
Age,
Mean y (SD)
Sex, %
Male
High-Risk
Antibiotics, %b
Allen et al, 201339 L. acidophilus CUL60, CUL21,
B. biﬁdum CUL20,
B. lactis CUL34
60 P 1,492 12 292 1,489 17 280 100 77.8 (8.1) 50.8 13.8
Bravo et al, 200829 S. boulardii 10.2 P 41 0 0 45 0 0 0 50.4 (19.1) 23.3 0
Duman et al, 200528 S. boulardii 10 SC 204 0 0 185 1 0 0 45.2 (13.4) 51.3 0
Ehrhardt et al, 201642 S. boulardii 9 P 246 2 7 231 2 3 100 58.4 (17.2) 56.4 8.9
Gao et al, 201027 L. acidophilus CL1285,
L. casei LBC80R
50; 100 P 170 9 0 83 20 0 100 59.6 (6.3) 51.8 29.2
Georgieva et al, 201541 L. reuteri DSM17938 0.10 P 49 0 ... 48 0 ... 100 ... ... 45.8
Hickson et al, 200732 L. casei imunitass DN-114 001,
L. bulgaris, S. thermophiles
40.74 P 69 0 ... 66 9 ... 100 73.8 (10.7) 45.9 19.3
Klarin et al, 200833 L. plantarum 299v 80 P 19 0 2 22 1 2 100 60.8 (17.2) 68.3 48.8
Kotowska et al, 200530 S. boulardii 30 P 119 3 0 127 10 0 23.2 3.8 (1.7–7.2)c ‡ 43.1 1.6
Lonnermark et al, 201043 L. plantarum 299v 100 P 81 0 0 82 0 0 54.6 47.7 (47.9) 44.2 24.5
Miller et al, 200834 L. rhamnosus GG 20 P 96 0 7 91 2 4 100 ... 50.0 62.1
Miller et al, 200835 L. rhamnosus GG 60 P 158 2 4 158 0 ... 100 ... 47.5 23.0
Plummer et al, 200436 L. acidophilus, B. biﬁdum 20 P 69 2 0 69 6 0 100 62.2 (19.0) 53.6 ...
Pozzoni et al, 201231 S. boulardii 10 P 141 3 0 134 2 0 100 79.2 (9.8) 49.8 76.7
Psaradellis et al, 201037 L. acidophilus CL1285,
L. casei LBC80R
50 P 216 2 ... 221 4 ... 100 62.1 (17.0) 49.0 ...
Ruszczynski et al, 200844 L. rhamnosus (2593 Pen, 2594
E/N, 2595 Oxy)
20 P 120 3 0 120 7 0 54.2 3.6 (1.5–6.6)c 54.0 9.6
Selinger et al, 201338 VSL#3d 900 P 116 0 6 112 0 6 100 57.3 (18.0) 52.6 11.0
Wong, 201440 L. casei Shirota 6.5 SC 76 0 ... 86 1 ... 100 50.2 (19.1) 80.5 85.4
NOTE. B, Biﬁdobacterium; CDI, Clostridium difﬁcile infection; CFU, colony-forming units; d, day; L, Lactobacillus; P, placebo; SAE, serious adverse events; SD, standard deviation; SC,
standard care.
aThe timing of administration and the duration of probiotics ranged from providing probiotics for the duration of antibiotic exposure and up to 7 d following completion of antibiotics.
Timing of administration ranged from immediately when starting antibiotics and up to 7 d following antibiotics.
bHigh-risk antibiotics were third- and fourth-generation cephalosporins, lincosamides, and ﬂuoroquinolones.
cMedian and interquartile range.
dB. breve, B. longum, B. infantis, L. acidophilus, L. plantarum, L. paracasei, L. bulgaricus, and S. thermophiles.
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interaction with the treatment effect (P= .007). Compared to
no probiotics, multispecies probiotics (OR, 0.33; 95% CI,
0.20–0.56; P< .0001; n= 5,074) (Figure 2) signiﬁcantly
reduced CDI, whereas the effect of single-species probiotics
was not statistically signiﬁcant (OR, 0.41; 95% CI, 0.17–1.00;
P= .051; n= 5,074) (Figure 2). Compared to no probiotics, a 1
billion CFU per day increase in dose did not signiﬁcantly
reduce CDI risk (OR, 0.99; 95% CI, 0.99–1.00; P= .108;
n= 5,074) (Figure 2).
Post hoc, we conducted a subgroup analysis of 5 trials using
S. boulardii (n= 1,473), the probiotic most commonly used
among RCTs for CDI prevention, and compared it with trials
using other strains (n= 5,381). We found no signiﬁcant
difference (OR, 0.86; 95% CI, 0.10–7.04) (Figure 2).
Sensitivity Analyses
When treating age as a categorical variable in the multivariate
analysis, the effect of probiotics remained similar (OR, 0.35;
95% CI, 0.22–0.55; P< .0001) (Figure 2). In a post hoc ana-
lysis, we removed infants <1 years of age, which resulted in a
similar summary estimate (OR, 0.37; 95% CI, 0.23–0.59;
P< .0001) (Figure 2). Results remained similar for the 18
studies in the unadjusted model regarding random-effects
aggregate-data meta-analysis (n= 6,447 participants; OR, 0.45;
95% CI, 0.30–0.68; P< .0001; I2= 8%), for the 13 studies
included in the adjusted model (n= 5,341 participants; OR,
0.42; 95% CI, 0.24–0.72; P= .002; I2= 21%), and when using
GEE for the adjusted analysis (OR, 0.47; 95% CI, 0.29–0.76;
P= .0022) (Figure 2).
Secondary Outcome: Serious Adverse Events
Of the 14 studies reporting on the incidence of SAEs, 318 of
2,556 cases (12.4%) were in the intervention group and 295 of
2,434 cases (12.1%) were in the control group (Table 1). There
was no signiﬁcant difference between groups (OR 1.06; 95%
CI, 0.89–1.26; P= .536) (Figure 3). There were no cases of
table 2. Summary Data From Trials Providing Individual Patient Data
Probiotics group (n= 3,482) Control Group (n= 3,369)
Variable
Valid
Sample Missing Measure
Valid
Sample Missing Measure
Age, mean y (SD) 3,151 331 63.8 (23.3) 3,047 322 63.3 (24.1)
<1 34 35
1 to <18 211 217
18 to <65 832 781
65 + 2,074 2,014
Sex (male, %) 3,317 165 1,747 (52.7) 3,201 168 1,587 (49.6)
Hospitalized, no. (%) 3,480 2 3,054 (87.7) 3,369 0 2,953 (87.7)
Length of hospital stay, median d (IQR) 2,608 874 7 (4–15) 2,498 871 7 (4–15)
Antibiotics class (any)a 2,812 299 2,812 2,697 307 2,697
Aminoglycoside 31 52
Beta-lactam ± 1,755 1,701
Beta-lactamase inhibitor
Carbapenem 49 48
Cephalosporin (1st generation) 296 254
Cephalosporin (2nd generation) 445 471
Cephalosporin (3rd generation)b 130 138
Cephalosporin (4th generation)b 1 3
Fluoroquinoloneb 323 322
Glycopeptide 148 130
Lincosamide 97 66
Macrolide 570 556
Others 697 700
High risk antibiotic at any time, no. (%)b 2,982 500 599 (20.1) 2,887 482 565 (19.6)
No. of antibiotics, median (IQR) 3,179 303 2 (1–2) 3,064 305 2 (1–2)
Antibiotic exposure, median d (IQR)a 1,447 1,474 10 (7–14) 1,337 1,592 10 (7–14)
Probiotics or Control Exposure, median d (IQR) 3,012 470 15 (11–21) 2,916 453 15 (10–21)
C. difﬁcile infection, no. (%) 3,384 98 38 (1.1) 3,261 108 82 (2.5)
Serious adverse events, no. (%) 2,556 683 318 (12.4) 2,434 935 295 (12.1)
aValues for antibiotic class and median, IQR for antibiotic exposure were computed based on studies who had these measures available within
data (43–45 were not included).
bHigh-risk antibiotics were considered 3rd- and 4th-generation cephalosporins, lincosamides, and ﬂuoroquinolones.
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bacteremia or fungemia, and none of the SAEs were deemed
attributable to probiotics, based on published ﬁndings and
correspondence with investigators. Similarly, there were no
differences among the 11 studies with data available for the
adjusted model (OR, 1.06; 95% CI, 0.89–1.28; P= .503)
(Figure 3). Increasing age (OR, 1.03; 95% CI, 1.02–1.04;
P< .0001), multiple antibiotic usage (OR, 1.60; 95% CI, 1.25–
2.05; P= .0002), and being treated with high-risk antibiotics
(OR, 1.36; 95% CI, 1.06–1.74; P= .015) were signiﬁcantly
associated with SAEs, whereas sex was not (Figure 3).
discussion
Our IPD meta-analysis of 18 trials with data on 6,851 partici-
pants found that probiotics reduced the risk of CDI by
two-thirds. The risk of SAEs was not signiﬁcantly different
between probiotics and control groups. Importantly, none of
the SAEs were attributable to probiotics. The quality (cer-
tainty) in the effect estimates for CDI was moderate, down-
graded due to a low number of events, while for SAEs the
certainty was moderate, downgraded for risk of publication
bias (Table 3).
Our results corroborate the ﬁndings in a previous aggregate-
data meta-analysis.12,47 Recent clinical practice guidelines
currently do not recommend probiotic prophylaxis, even
though probiotics have the highest quality evidence among
cited prophylactic therapies, including antibiotic stewardship,
hypochlorite solutions, and bundle strategies.14
Some suggest that probiotics are most likely to be of beneﬁt
in high CDI incidence settings.48,49 Data on disease pressure
were not available; thus, we approximated the baseline CDI
risk using the control group event rates of individual trials.
ﬁgure 1. Flow of eligible studies providing and not providing individual patient data.
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This analysis suggested that CDI incidence ≥5% interacts with
the overall group effect, suggesting that probiotics may be
more effective when the baseline CDI risk is moderate to high.
Considering the absolute risk reduction (ARR) and corre-
sponding number needed to treat (NNT), if the baseline CDI
risk is 1.6% (median of all studies), the observed effect (OR,
0.35) corresponds to an ARR of ~ 1.0% and an NNT of 96.
Using the same effect estimate, given the mean baseline, CDI
risk across all studies is 4.34%, and the ARR will be 2.8%
(NNT, 35).
Combining different probiotic species and strains in meta-
analyses is a contentious issue. Some suggested that pooling
different probiotic agents is problematic,50 while others sug-
gested that pooling probiotics and subsequently assessing any
differences using a priori subgroup analysis based on species,
strain, and dose is in accordance with standard meta-analysis
methods.12 As with previous aggregate-data meta-analyses, we
found no signiﬁcant difference between species or strains,
suggesting that speciﬁc effects based on the type of probiotic
may not be an important factor to consider when choosing a
probiotic. Instead, it is probably more important to consider
the quality of the product and credibility of the manufacturer51
and to use a product that has been investigated in RCTs,
particularly a multistrain product given our ﬁndings.
However, as is typical of subgroup assessments, our analysis is
likely underpowered. For example, we rated downward for
precision for each of our outcomes. For single species and
multispecies probiotics, our data suggest that while both
reduce CDI compared to no probiotics, multispecies probio-
tics demonstrated a statistically signiﬁcant treatment effect
compared to no probiotics, whereas single-strain probiotics
did not. One hypothesis is that multiple species may have an
additive effect or may be associated with a higher dose. Among
studies of multistrain probiotics,29,34,38–41,46 the daily median
value was 50 billion CFU per day; in studies with single-strain
probiotics,30–33,35–37,42–45 the daily median value was 15.6
billion CFU per day. However, in exploring the impact of dose
response, we found no statistically signiﬁcant trend. Failure to
ﬁgure 2. Incidence of Clostridium difﬁcile infection.
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ﬁnd a dose effect may represent the variability in dose admi-
nistered (viable organisms per capsule) as well as the potential
variability between studies with respect to whether the
consumed dose survived gastric passage (viable organisms
arriving in small and subsequently large bowel). Both are
important areas of inquiry for future studies.
ﬁgure 3. Incidence of serious adverse events.
table 3. Summary of Findings Table Based on Adjusted Analysisa
Control
Group
Probiotic
Group
Outcomes
No. of
Participants
(No. of Studies)
Relative Effect,
Odds Ratio
(95% CI)
Assumed
Risk per
1,000b
Comparative
Risk
per 1,000
(95% CI)b
Quality of
Evidence
(GRADE)c
CDI deﬁned by: cytotoxin and/or culture 5,074 (13) 0.35 (0.23–0.55) 27 12 (8–16) Moderated
Serious adverse events deﬁned by author report and/or IPD 4,714 (11) 1.06 (0.89–1.28) 122 123 (110–136) Moderatee
NOTE. CI, conﬁdence interval; OR, odds ratio; GRADE, working group grades of evidence; CDI, Clostridium difﬁcile infection; SAE, severe adverse
event; IPD, individual participant data; RCT, randomized controlled trial.
aPatient or population: adults and children exposed to antibiotics. Settings: inpatient and outpatient. Intervention: probiotics.
bRisk for the control group represents mean rate across studies. Risk for probiotics group is calculated by applying the relative effect rate to the
control risk.
cHigh quality: further research is very unlikely to change our certainty in the estimate of effect. Moderate quality: further research is likely to have
an important impact on our certainty in the estimate of effect and may change the estimate. Low quality: further research is very likely to have an
important impact on our certainty in the estimate of effect and is likely to change the estimate. Very low quality: we are very uncertain about the
estimate.
dWe rated CDI down for imprecision because of a low number of total events (<300).
eWe rated SAEs down for risk of publication bias as we were only able to obtain IPD for 18 of 32 RCTs and among the IPD trials only 11 trials
(n= 4,718) could be included in our adjusted analysis.
8 infection control & hospital epidemiology
Our study has several strengths. First, we used a comprehensive
search; we had a high response rate from study authors52; and we
were able to obtain 18 of 32 trials, including the 2 of the largest trials
to date,41,44 one of which enrolled almost 3,000 participants.41 Our
unadjusted effect estimates across primary and secondary outcomes
were similar to studies for which we did not have IPD available,
making the presence of a selection bias unlikely. Our analyses were
robust to sensitivity analyses using different analytic methods,
including categorization of age, aggregate-data meta-analyses, GEE
analysis, and missing participant outcome data.
Several limitations must be emphasized. First, data for adjus-
tedmodels were not available in ~ 25% of participants. However,
as the estimates were similar for the unadjusted model and
adjusted IPDmodel, and the aggregate-data meta-analysis, this is
unlikely to have introduced a signiﬁcant bias. Second, data were
too limited to allow an examination of each class of antibiotic
separately; thus, we categorized antibiotics as high risk versus not
high risk.53 For the same reason, we were unable to follow our a
priori protocol to adjust for other potentially important
confounding factors such as length of antibiotic exposure and
length of hospitalization stay. Third, missing participant
outcome data was a common issue across trials. Our multiple
imputation analysis, however, suggested that outcomes were
similar for participants with and without missing data. The
incidence of CDI may be underestimated, given that 71 of 760
participants (9%) with diarrhea were not tested for CDI. This
affected participants in the intervention and control groups
equally; thus, it is unlikely to have biased the results.
Moderate quality (ie, certainty) evidence suggests that pro-
biotic prophylaxis is a useful CDI prevention strategy, parti-
cularly among participants taking 2 or more antibiotics and in
hospital settings where the risk of CDI is ≥5%. There was no
evidence for concern regarding serious adverse events related
to the preparations evaluated. Patients may value the absolute
risk reduction (1.0%; NNT, 96) we found, speciﬁcally among
those probiotics with the largest body of evidence for efﬁcacy
and safety. The observation that probiotic prophylaxis is of
greater beneﬁt in populations with a moderate-to-high base-
line risk should inform site selection in future studies, as
should the use of probiotics in clinical settings.
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